Sarepta Therapeutics | SRPT - 营业费用



金融业
股票价格
USD
资产
USD 3.19B
现金及等价物
USD 571.15M
销售成本
USD 150.1M
流动资产
USD 2.22B
流动负债
USD 502.91M
债务
USD 1.04B
EBIT
USD 13.29M
EBITDA
USD 375.48M
员工
1.37K
EPS每股收益
USD 0.64
股本和储备
USD 1.53B
销售毛利
USD 251.15M
债务利息支出
USD 21.51M
利息收入
USD 7M
贷款资金
USD 847.62M
市值
USD 2.05B
净收入
USD 330.96M
营业费用
USD 387.96M
营业利润
USD 13.29M
普通股股本
USD 105.62M
PE价格收益
27.27
税前利润
USD -1.75M
销售收入
USD 401.3M
销售和管理费用
USD 107.6M
股票
USD 904.27M
贸易债权人
USD 50.98M
应收帐款人
USD 393.8M


营业费用 更改 日
Acadia Pharmaceuticals USD 270.12M 2.55M 2026-06
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Alnylam Pharmaceuticals USD 1.06B 160.97M 2026-06
Amgen USD 11.69B 6.9B 2026-06
BioCryst Pharmaceuticals USD 119.78M 673.63M 2026-06
Biogen USD 2.98B 1.02B 2026-06
BioMarin Pharmaceutical USD 6.32B 5.69B 2026-06
Capricor Therapeutics USD 29.16M 2.87M 2025-12
Daiichi Sankyo JPY 489.64B 21.08B 2026-06
Eli Lilly USD 10.52B 496M 2026-06
Gilead Sciences USD 3.95B 19.57B 2026-06
Incyte USD 973.64M 4.65B 2026-06
Insmed USD 526.79M 20.55M 2026-06
Ionis Pharmaceuticals USD 370.24M 6.24M 2026-06
Moderna USD 960M 817M 2026-06
Nektar Therapeutics USD 49.12M 8.22M 2026-03
Neurocrine Biosciences USD 739.1M 139.2M 2026-06
Novavax USD 126.2M 23.62M 2025-12
Pfizer USD 85.19B 4.91B 2026-06
PTC Therapeutics USD 226.66M 19.64M 2026-03
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Roche Holding CHF 18.9B 2.12B 2026-06
Sangamo BioSciences USD 33.87M 12.89M 2024-06
Sanofi EUR 9.92B 607M 2026-06
Sarepta Therapeutics USD 387.96M 15.59M 2026-06
Tectonic Therapeutic USD 27.3M 5.78M 2026-03
Ultragenyx Pharmaceutical USD 289M 16M 2026-06
Vertex Pharmaceuticals USD 2.07B 217.1M 2026-06